Overview

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Status:
Completed

Trial end date:
2017-03-29

Target enrollment:

Participant gender:

Summary

This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device. MR901 is a code used to identify the combination of talaporfin sodium and the drug-activating device. Two different light doses will be tested against placebo groups in this 4-arm study.

Phase:

Phase 2

Details

Lead Sponsor:

Light Sciences Oncology

Collaborator:

Mundipharma Research Limited

Treatments:

Talaporfin